Myoview (Tetrofosmin)

Tetrofosmin is a lipophilic cation that readily enters viable heart cells in proportion to regional blood flow. Its gamma‑emitting properties enable SPECT cameras to create detailed images of myocardial perfusion, reflecting the functional status of coronary circulation.

The specific dose of Myoview is determined by the prescribing physician based on the imaging protocol, patient weight, and clinical indication. Healthcare professionals calculate the appropriate activity to achieve optimal image quality while adhering to radiation safety guidelines.

Safety data for tetrofosmin in pregnancy and lactation are limited. It is generally avoided unless the diagnostic benefit outweighs potential risks. Women who are pregnant or breastfeeding should discuss alternatives with their healthcare provider.

To order Myoview, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Myoview (tetrofosmin) and agents such as technetium‑99m sestamibi share similar imaging principles, but tetrofosmin has a slightly higher myocardial uptake and faster clearance, which can improve image contrast and reduce background activity. Choice of agent depends on local practice, availability, and specific protocol requirements.

Myoview must be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Before use, the vial should be inspected for particulate matter and only prepared under aseptic conditions as directed by the manufacturer.

Myoview is administered as an intravenous injection. The radiopharmaceutical is typically injected as a bolus or slow infusion, followed by a waiting period to allow myocardial uptake before SPECT imaging is performed according to the prescribed protocol.

Serious risks include rare anaphylactic reactions, severe hypotension, and life‑threatening arrhythmias. Because Myoview involves ionizing radiation, appropriate radiation safety measures must be observed to protect patients and staff.

Myoview should be avoided in patients with known hypersensitivity to tetrofosmin or any component of the preparation, in those with uncontrolled severe hypotension, and in pregnant or breastfeeding women unless the diagnostic benefit clearly outweighs the potential risk.